Institute of Cancer Research UK has identified proteolysis targeting chimeras (PROTACs) comprising a Von Hippel-Lindau disease tumor suppressor (VHL) binding moiety coupled to a receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) targeting moiety via a linker.
Hainan Simcere Pharmaceutical Co. Ltd. has synthesized protein degradation inducers comprising a regulator and/or promoter of protein proteasomal degradation moiety covalently linked to a protein targeting moiety through a linker reported to be useful for the treatment of cancer.
Gilead Sciences Inc. has disclosed protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.
Urachal carcinoma is a rare cancer which lacks a standard drug therapy, and for which knowledge regarding its immunohistochemical features remains unclear. The aim of a recently reported investigation was finding potential markers and targets for urachal carcinoma based on antibody-drug conjugate targets, as well as its association with prognosis.
Solid tumors are difficult to treat due to their heterogeneity and limited blood supply, which restrict the effective delivery of anticancer drugs. Macrophages are abundant in solid tumor tissues and are the only cell type actively infiltrating hypoxic tumor regions, making them a promising option for delivering therapeutic agents directly to tumors.
The transcription factor nuclear factor-κB (NF-κB) family has a central regulatory role in the expression of many genes related to immune responses, inflammation, cell survival and cancer. Previous evidence demonstrated causal links between a dysregulated noncanonical NF-κB signaling and several cancer types and autoimmune diseases, yet specific inhibitors targeting this pathway remain scarce.
Researchers from Zhengzhou University and affiliated organizations published data from a study that aimed to assess the expression levels of histone modifier enzymes in esophageal squamous cell carcinoma (ESCC).
Bispecific T-cell engager (BiTE) antibodies have shown efficacy in hematological malignancies and are being tested in a variety of solid tumors. Other strategies including bispecific antibodies in combination with monoclonal antibodies or targeting two different immune checkpoints on T cells are also undergoing clinical development.
Right open reading frame kinase 2 (RIOK2) plays an essential role in ribosome assembly and cell growth, survival and stress responses. Research has linked RIOK2 to tumor progression and poor prognosis in several types of cancer such as breast, lung, prostate or hematological tumors.
The research on glioblastoma requires the development of new preclinical murine models. The GL261 cell line forms glioma-like tumors in a reliable manner when transplanted intracranially, but these tumors do not completely mimic human glioblastoma. This model responds well to immune checkpoint inhibitors (ICIs), but ICIs have shown limited efficacy in some clinical trials.
RSS
